[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemodialysis-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemodialysis-complication":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,50,91,118,148,174,197,216,247,269,295,316,341,370,393],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100637600","the-effect-of-intradialytic-eye-exercise-in-hemodialysis-patients-100637600",false,"NCT07591714","The Effect of Intradialytic Eye Exercise in Hemodialysis Patients","The Effect of Intradialytic Eye Exercise on Physical Function, Balance, and Fall Risk in Hemodialysis Patients: A Randomized Pilot Trial","Inclusion Criteria\n\n* Adults ≥18 years receiving maintenance in-center hemodialysis\n* Clinically stable for brief seated intradialytic intervention\n* Able to understand and follow eye-exercise instructions\n* Able to provide informed consent\n* Able to sit upright independently during dialysis\n* Able to complete repeated outcome assessments\n* Able to communicate discomfort or adverse symptoms\n* Usual corrective lenses permitted if needed for visual clarity\n\nExclusion Criteria\n\n* Unstable cardiac conditions (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, uncontrolled arrhythmia)\n* Active infection or acute medical illness\n* Hemodynamic instability\n* Significant cognitive or communication impairment preventing instruction-following\n* Severe uncorrected visual impairment or active ocular disease\n* Recent major ophthalmologic surgery\n* Severe musculoskeletal or neurologic limitations preventing participation or testing\n* Any condition deemed unsafe for intradialytic exercise by the treating physician or nephrologist","ALL","18 Years","80 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This pilot randomized trial will evaluate whether a structured intradialytic eye-exercise program can be delivered safely and consistently during maintenance hemodialysis and whether it shows preliminary promise for improving physical function, balance, and fall-related concern. The study is needed because hemodialysis patients commonly experience impaired physical performance, reduced balance, and fear of falling, and these problems are associated with higher fall risk; at the same time, supervised exercise during dialysis is increasingly viewed as a practical way to reach this medically complex and often sedentary population. Eye-movement and gaze-stability training has also shown benefit for balance- and fall-related outcomes in older adults and stroke survivors, but its feasibility and potential value during dialysis sessions remain uncertain.",[27,28],"End Stage Renal Disease","Hemodialysis Complication",[30,31,32,33,34,35,36],"Eye exercise","Gaze stabilization exercise","Home based exercise","Hemodialysis","Balance impairment","Fall risk","Physical function","NOT_YET_RECRUITING","2026-05-15",{"date":40,"type":41},"2026-05-18","ACTUAL",{"date":43,"type":21},"2026-06",{"date":45,"type":21},"2026-09",{"name":47,"class":48},"Pardis Specialized Wellness Institute","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":72,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":49},"100594451","chlorhexidine-caps-for-clabsi-prevention-in-hemodialysis-a-pilot-randomized-controlled-trial-100594451","NCT07019610","Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial","Evaluation of Chlorhexidine Caps for Central Line Associated Blood Stream Infection Prevention in People Needing Hemodialysis: a Pilot Randomised Control Trial","ECHO-HD","Inclusion Criteria:\n\n* Age≥18\n* Able to provide informed consent\n* Kidney failure requiring a tunnelled CVC for treatment (haemodialysis)\n* 21 days BSI free\n* No known allergy to chlorhexidine and\u002For nylon and\u002For polypropylene.\n\nExclusion Criteria:\n\n* Current CLABSI\n* Known allergic to chlorhexidine and\u002For nylon and\u002For polypropylene.\n* Patients on an end-of-life pathway\n* People with a cognitive impairment and\u002For intellectual disability",{"count":59,"type":21},60,[24],"The goal of this clinical trial is to compare a chlorhexidine antimicrobial barrier cap in patients requiring hemodialysis treatment to the standard hemodialysis caps currently used within the Metro North Kidney Health Service.\n\nThe main questions to answer are:\n\n* Study Feasibility\n* Occurrence of infectious complications related to renal central venous catheters\n\nParticipants will be randomly allocated to receive either of the below hemodialysis caps to cover their hemodialysis catheter hub:\n\n* The standard hemodialysis cap used at the Royal Brisbane and Women's Hospital, or\n* The intervention hemodialysis cap containing chlorhexidine inside it\n\nResearchers will compare standard and chlorhexidine hemodialysis caps to see if the presence of chlorhexidine improves the occurrance of infectious complications related to the hemodialysis catheter.",[63,64,65,66,67,68,69,70,71,28],"Vascular Access Complication","Device Related Infection","Device Related Sepsis","Catheter Infection","Catheter Complications","Catheter-Related Infections","Catheter Related Complications","Hemodialysis Catheter Infection","Hemodialysis Catheter-associated Infection",[73,74,75,76,77,78,79,80,81,82],"Hemodialysis Catheter","Randomised Controlled Trial","Antimicrobial Barrier Caps","Vascular access device","Hemodialysis catheter caps","Chlorhexidine cap","Central Venous Catheter","CVC","CLABSI","Central Line Associated Blood Stream Infection","2026-04-27",{"date":85,"type":41},"2026-04-29",{"date":43,"type":21},{"date":88,"type":21},"2028-02",{"name":90,"class":48},"The University of Queensland",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100632377","the-effect-of-progressive-muscle-relaxation-exercises-on-depression-and-fatigue-in-patients-receiving-hemodialysis-treatment-a-randomized-controlled-trial-100632377","NCT07512895","The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\nScoring 4 or above on the First-Level Beck Depression Inventory\n\nPatients who regularly receive hemodialysis treatment\n\nIndividuals who are cognitively capable of understanding the exercise instructions\n\nIndividuals who voluntarily agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\nIndividuals diagnosed with a psychiatric disorder (e.g., major depression, bipolar disorder, schizophrenia, etc.)\n\nIndividuals who are physically unable to perform relaxation exercises due to musculoskeletal disorders\n\nIndividuals who have previously participated regularly in relaxation therapy, yoga, meditation, or similar practices\n\nIndividuals who cannot follow instructions due to hearing, visual, or cognitive impairments\n\nIndividuals who are simultaneously participating in another psychosocial or physical intervention program\n\n\\-",true,"75 Years",{"count":59,"type":21},[24],"This study aims to evaluate the effects of progressive muscle relaxation exercises on depression and fatigue levels in patients undergoing hemodialysis treatment. Progressive muscle relaxation is applied as an individualized non-pharmacological intervention, and its potential contribution to psychological well-being is investigated. The study seeks to determine whether regular relaxation exercises can reduce depressive symptoms, alleviate fatigue, and improve overall emotional well-being in hemodialysis patients. Findings from this research are expected to provide evidence for the use of relaxation-based interventions as supportive care methods in the management of psychological symptoms associated with chronic kidney disease and hemodialysis.",[28,33],[104,33,105,106],"Depression","Progressive Muscle Relaxation Exercises","Fatigue","RECRUITING","2026-04-02",{"date":110,"type":41},"2026-04-06",{"date":112,"type":41},"2025-12-01",{"date":114,"type":21},"2026-05-01",{"name":116,"class":48},"Istanbul Aydın University",2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":49},"100608820","effect-of-modifying-magnesium-concentration-in-citrate-enriched-dialysate-on-hemodialysis-associated-thromboinflammation-100608820","NCT07206524","Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation","Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation: a Local Pilot OMAGOD Plus Trial","pilot OMAGOD +","Inclusion Criteria:\n\n* Participants to the OMAGOD pilot trial\n\nExclusion Criteria:\n\n* Patients who are not participating in the OMAGOD pilot trial",{"count":5,"type":21},[24],"This clinical trial investigates whether the composition of dialysate influences hemodialysis-associated thromboinflammation. Specifically, it evaluates the effects of magnesium concentration and acid type in dialysate on immune cell activation and thromboinflammatory responses.\n\nPatients participating to the multicentric pilot OMAGOD trial will be invited to participate to this monocentric plus study.\n\nIn the pilot OMAGOD trial, participants will undergo standard hemodialysis (3 sessions\u002Fweek, 4 hours each) and receive three different dialysate compositions in a crossover design. Each treatment phase lasts two weeks (six sessions).\n\nFor the local plus study, during selected sessions (3 per patient - midweek hemodialysis session of the last week of a treatment period), blood samples will be collected (at baseline, hourly, and at the end of dialysis) and additionally, after each session, the used dialysis circuit will be rinsed to recover adherent cells.\n\nThe study aims to:\n\n* Assess whether the dialysate composition influences leukocyte and platelet activation .\n* Evaluate whether the dialysate composition influences neutrophil extracellular trap (NET) formation.\n* Identify novel biomarkers of thromboinflammation using transcriptomic analysis of immune cells.",[33,130,28,131],"Thromboinflammation","End Stage Renal Disease (ESRD)",[133,134,135,136,137,138],"hemodialysis","thromboinflammation","neutrophil extracellular trap formation","dialysate composition","cellular activation","transcriptome analysis","2025-11-14",{"date":141,"type":41},"2025-11-17",{"date":143,"type":41},"2025-06-05",{"date":145,"type":21},"2026-12",{"name":147,"class":48},"Universitair Ziekenhuis Brussel",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":49},"100596598","a-study-of-real-world-events-of-vericiguat-in-patients-with-chronic-kidney-disease-and-heart-failure-100596598","NCT07047547","A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure","A Prospective, Observational, Single-arm Study to Evaluate the Efficacy and Safety of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure.","ESVGR-HF","Inclusion Criteria:\n\n* The patient is aged between 18 and 80 years\n* Suffering from chronic kidney disease (eGFR\\\u003C90ml\u002Fmin\u002F1.73m², by CKD-EPI formula).\n* They have chronic heart failure (NYHA class ≥II), with reduced ejection fraction, defined as LVEF≤50%.\n* Their serum potassium level has been ≤4.8 mmol\u002FL in the past month.\n* For women of childbearing potential, the pregnancy test result is negative at the screening visit and they agree.\n* Adequate contraceptive measures are taken.\n* The patient's dialysis adequacy assessment has reached Kt\u002FV \\>1.2, or URR\\>70%.\n* The study protocol is implemented after being approved by the hospital ethics committee, and all patients voluntarily participate in this study\n\nExclusion Criteria:\n\n* Acute renal failure.\n* Systolic blood pressure below 90 mmHg at screening (systolic blood pressure less than 95 mmHg during interdialytic period).\n* Isolated right heart failure due to pulmonary disease; the primary cause of dyspnea is due to non-cardiac, non-heart failure reasons, such as acute or chronic respiratory diseases.\n* History of myocardial infarction or cerebrovascular event within the past 3 months.\n* History of angioedema.\n* Hemodialysis patients with dialysis frequency less than 3 times per week.\n* Significant laboratory abnormalities at screening that interfere with the assessment of the safety or efficacy of the study drug (e.g., serum potassium \\> 5.5 mmol\u002FL or \\\u003C 3.5 mmol\u002FL, serum sodium \\\u003C 130 mmol\u002FL, or alanine aminotransferase or aspartate aminotransferase \\> 2 times the upper limit of the normal range).\n* History of kidney transplantation or planned kidney transplantation within the next 12 months.\n* Use of medications for pulmonary arterial hypertension, such as sildenafil, during the study period.\n* Known allergy to the study treatment (active substance or excipients).\n* Any other disease or treatment that makes the patient ineligible to participate in this study or to complete the entire planned study period (e.g., active malignancy or other diseases that limit life expectancy to less than 12 months).\n* Pregnant or breastfeeding during the study period, or intending to become pregnant.",{"count":157,"type":21},118,[24],"Chronic Kidney Disease often requires dialysis and other treatments to sustain life, and patients frequently suffer from heart failure, which exacerbates the disease burden. Research has shown that the incidence of heart failure is high among patients on dialysis, and the prognosis is poor. In recent years, there has been significant progress in the treatment of heart failure. Vericiguat, a novel sGC stimulator, can improve cardiac function and exercise tolerance, reduce the risk of cardiovascular death and hospitalization for heart failure, and has good tolerance. It has been included in relevant guidelines as a recommended drug. It has good tolerance in patients with renal insufficiency, and its therapeutic effect is consistent in patients with different levels of eGFR. However, there is a lack of prospective, randomized controlled studies targeting the special population of patients on dialysis. This study is a prospective, observational, single-arm study, planning to recruit 118 patients from June 2025 to June 2026. It aims to assess the efficacy and safety of Vericiguat in patients with heart failure on hemodialysis, to provide new evidence-based medical evidence for the treatment of heart failure in this special population, optimize the treatment strategy, and improve the prognosis and quality of life.",[28,161],"Heart Failure",[163,164,28],"Vericiguat","Heart failure","2025-07-03",{"date":167,"type":41},"2025-07-09",{"date":169,"type":41},"2025-06-01",{"date":171,"type":21},"2026-06-01",{"name":173,"class":48},"Guangdong Provincial People's Hospital",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":180,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":49},"100597156","effect-of-intradialytic-resistance-versus-aerobic-exercise-on-cardiovascular-system-in-patients-on-regular-hemodialysis-100597156","NCT07054827","Effect of Intradialytic Resistance Versus Aerobic Exercise on Cardiovascular System in Patients on Regular Hemodialysis","Inclusion Criteria:\n\n* End-stage renal disease (ESRD) or stage 5 chronic kidney disease (CKD) in which on maintenance regular HD (three sessions\u002Fweek (on alternate days), for four hours\u002Fsession for more than a year to five years when starting the study.\n* Both gender male and female aged from 45 to 60 years old.\n* Patients with intradialytic hypotension sudden drops of systolic pressure of more than 20 mm Hg or diastolic pressure of more than 10 mmHg.\n* Receiving hemodialysis (HD) through uncomplicated arm arteriovenous (A-V) fistula.\n* Patients with Body Mass Index (BMI): 18,5 \\\u003C 30kg\u002Fm2.\n* In a stable medical, clinical, and hemodynamic condition\n* Untrained at baseline and did not participate in any regular physical activity before.\n\nExclusion Criteria:\n\n* Severe Chest diseases (either obstructive or restrictive).\n* Clinical signs of a severe cardiac event. (eg, severe atherosclerosis, congestive heart failure),\n* Severe psychiatric or cognitive impairment, who unable to follow comment.\n* Neurological disorders affecting respiratory muscles or any muscular dystrophies (cervical disc or bulge).\n* Patients with severe self-limiting illness (e.g., cancer).\n* Patients with Body Mass Index (BMI) \\> 30kg\u002Fm2.\n* Previous renal transplantation patients.\n* Pregnant females or became pregnant during the study.\n* Patients started HD in less than a year or more than 5 years.\n* Hospitalized during the prior month.\n* Patients who were irregular in HD or not adherent to the exercise program.","FEMALE","45 Years","65 Years",{"count":184,"type":21},75,[24],"The purpose of the study is to compare the effect of resistance exercise and aerobic exercise on intradialytic hypotension in patients undergoing hemodialysis.",[28],"2025-06-28",{"date":190,"type":41},"2025-07-08",{"date":192,"type":21},"2025-07-05",{"date":194,"type":21},"2025-11-20",{"name":196,"class":48},"Cairo University",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":182,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":49},"100591097","effect-of-the-postbiotics-on-complications-treatment-in-elderly-hemodialysis-patients-100591097","NCT06975995","Effect of the Postbiotics on Complications Treatment in Elderly Hemodialysis Patients","A Postbiotics Improves the Quality of Life and Nutritional Status in Elderly Hemodialysis Patients","Inclusion Criteria:\n\nInvestigators must maintain a screening log of all potential study candidates that includes limited information about the potential candidate, date, and outcome of the screening process (e.g. enrolled into study, reason for ineligibility, or refused to participate). After signing an informed consent form, potential patients must meet all of the criteria:\n\n1. Age ≥65 years.\n2. Receiving maintenance hemodialysis therapy for at least 6 months.\n\nExclusion Criteria:\n\nThe following exclusion criteria must NOT be present for each subject:\n\n1. Subjects with medical history that might affect oral feeding (e.g. intestinal obstruction, gastrointestinal bleeding, acute pancreatitis and accidental inhalation) within the last 1 month prior to screening.\n2. Subjects with medical history that might affect gastrointestinal functions (e.g. inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), short bowel syndrome (SBS), et al.).\n3. Subjects who cannot communicate and collaborate normally.",{"count":59,"type":21},[24],"The purpose of the trial is to explore the effect of exogenous postbiotics supply on the quality of life and nutritional status of elderly hemodialysis patients.\n\nParticipants will be devided into intervention group and placebo group in an 1:1 ratio.They will:\n\n1. In the treatment period for 12 weeks, intervention group receives postbiotics product while the other group receives placebo.\n2. In the subsequent 12 weeks, intervention group ends the trial and placebo group enters into remedial treatment period. Placebo group will receive postbiotics product for 12 weeks.\n\nResearchers will analyze the change of indicators such as quality of life and nutrition state of participants from the baseline to end of treatment, and compare the difference between the two group.",[28],"2025-05-08",{"date":210,"type":41},"2025-05-16",{"date":212,"type":41},"2024-08-01",{"date":145,"type":21},{"name":215,"class":48},"Peking University First Hospital",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100582868","six-month-response-rate-according-to-two-surgical-techniques-rotational-atherectomy-versus-angioplasty-to-treat-stenosis-of-vascular-accesses-in-hemodialysis-100582868","NCT06868901","Six-month Response Rate According to Two Surgical Techniques (Rotational Atherectomy Versus Angioplasty) to Treat Stenosis of Vascular Accesses in Hemodialysis.","Evaluation of the 6-month Response Rate According to Two Surgical Techniques (Rotational Atherectomy vs. Angioplasty) to Treat Stenosis of Vascular Accesses in Hemodialysis. A Single-center, Randomized, Single-blind, Superiority-controlled Pilot Study.","ARSAV","Inclusion Criteria:\n\n* Hemodialysis patient on arteriovenous fistula (AVF) with re-stenosis defined on echodoppler by a combination of \\>50% venous lumen reduction with a systolic peak ratio \\>2 associated with either : i) an internal residual diameter of \\\u003C 2 mm, or ii) a flow reduction \\> 25% or a flow rate \\\u003C 500 ml\u002Fmin.\n* Patient with at least one history of angioplasty on his\u002Fher AVF at the same site.\n* Patient available for 6-month follow-up.\n* Patient with free and informed consent and signed consent form.\n* Patient affiliated with or benefiting from a health insurance plan.\n\nExclusion Criteria:\n\n* Patient with an intraoperative technical impossibility.\n* Patient with a septic complication.\n* Patient participating in another interventional trial.\n* Patient in an exclusion period determined by another study.\n* Patient under court protection, guardianship or curatorship.\n* Patient unable to give consent.\n* Patient for whom it is impossible to give informed information.",{"count":225,"type":21},40,[24],"A well-functioning hemodialysis vascular access is a decisive factor in the survival of hemodialysis patients, who have a high mortality rate. 85% of these hemodialysis patients, are treated via an arteriovenous fistula (AVF). However, the primary patency of AVFs at 1 year is 60%, mainly due to neointimal hyperplasia developing in the drainage vein, which leads to stenosis and, if left untreated, thrombosis of the AVF. Indeed, forty percent of hemodialysis patients require re-intervention on their vascular access within the year, due to stenosis on their AVF.\n\nTransluminal angioplasty (TLA) is currently used as first-line treatment for these stenoses but TLA itself causes vascular damage, with early recurrence of the stenosis in 50% of cases at 6 months, and necessitating repeated interventions.\n\nIn recent years several endovascular techniques have been developed to limit the risk of re-stenosis, none of which have produced significantly better results than simple TLA. Eliminating intimal hyperplasia using a minimally invasive endovascular technique, rather than crushing it with simple angioplasty, would improve restenosis-free survival in these patients.\n\nToday, endovascular rotational atherectomy techniques are available to improve the patency of angioplasty in the treatment of complex arterial lesions of the coronary arteries and lower limbs. The atherotome is a guide-mounted catheter with a small burr at its distal end, which resects the atheromatous plaque whereas angioplasty simply crushes it. Atherectomy is followed by drug-eluting balloon (DEB) angioplasty with paclitaxel release to limit restenosis through its anti-inflammatory and anti-proliferative activity. A few cases of rotational atherectomy for the treatment of calcified stenoses in saphenous vein coronary bypasses have been reported in the literature, with encouraging results. If AVF re-stenosis should occur, the intimal hyperplasia can be removed endovascularly, thereby limiting the risk of short-term iterative stenosis.\n\nThe aim of this study was to compare the 6-month re-stenosis rate with this technique (atherectomy + drug-eluting balloon) versus standard angioplasty + drug-eluting balloon for the treatment of restenosis of hemodialysis vascular accesses.",[28,229,230],"Dialysis Access Malfunction","Stenosis",[232,233,234,235,236,237],"Arteriovascular fistula","Angioplasty","Balloon","Atherectomy","Fistula","Re-stenosis","2025-03-05",{"date":240,"type":41},"2025-03-11",{"date":242,"type":21},"2025-03-01",{"date":244,"type":21},"2027-12-01",{"name":246,"class":48},"Centre Hospitalier Universitaire de Nīmes",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":256,"studyType":257,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100561184","outcome-and-complications-of-regular-hemodialysis-100561184","NCT06586853","Outcome and Complications of Regular Hemodialysis","Assessment of Complications and Outcome of Regular Hemodialysis Patients in Upper Egypt: Two Center Prospective Study","Inclusion Criteria:\n\n1. Aged ≥ 18 years old.\n2. Patients receiving regular maintenance hemodialysis for at least three months\n3. Patients receiving regular hemodialysis (three times a week for four hours each session).\n4. Patients treated at an in-center hemodialysis\n\nExclusion Criteria:\n\n1. Patients treated with a home-based hemodialysis .\n2. Non end stage renal disease patients undergoing hemodialysis due to any other indication.\n3. Refuse to share in the study",{"count":255,"type":21},300,"1 Year","OBSERVATIONAL","Assessment of the major hemodialysis outcomes which are vascular access events, mortality and hospitalization Quality of life in end stage renal disease (ESRD) patients undergoing regular hemodialysis in upper Egypt and analysis of the major hemodialysis outcomes along a one year duration.",[28],"2024-09-05",{"date":262,"type":41},"2024-09-19",{"date":264,"type":21},"2024-10-01",{"date":266,"type":21},"2025-10-01",{"name":268,"class":48},"Assiut University",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":97,"sex":16,"minAge":276,"maxAge":18,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":49},"100560322","exercise-therapy-on-rheological-functions-of-erythrocyte-in-hemodialysis-100560322","NCT06575634","Exercise Therapy on Rheological Functions of Erythrocyte in Hemodialysis","Effects of Supervised Exercise on Rheological Functions of Erythrocyte in Patients With End-Stage Renal Disease on Hemodialysis","Inclusion Criteria:\n\n* Receiving hemodialysis and medication at least for 6 weeks\n* Kt\u002FV score \\> 1.2\n\nExclusion Criteria:\n\n* Under 20 years-old\n* Hyperkalemia occurs within 3 month\n* Having orthopedic or muscular diseases\n* Other concerned medical, psychological or physiological diseases\n* Pregnancy\n* Other exercise contraindications","20 Years",{"count":278,"type":21},180,[24],"To improve aerobic capacity, muscular function, and health-related quality of life in patients with end-stage renal disease (ESRD), regular exercise is recommended. Supervised intradialytic exercise at moderate intensity is a viable approach to ensure patient safety, maintain compliance, and effectively enhance physiological adaptations. However, the impact of exercise training on erythrocyte rheological properties in ESRD patients, such as red blood cell deformability, aggregation, and oxygen transport capacity, remains unclear.\n\nMethod: ESRD patients (anticipated n=180) will undergo supervised exercise training therapy three times per week for six months in the hospital, followed by three months at home. Cardiopulmonary exercise tests will be conducted before and after the intervention. Erythrocyte deformability and aggregation will be assessed using a laser-assisted optical rotational cell analyzer (LORCA), while additional protein levels and reactive oxygen species (ROS) status will be measured using a flow cytometer. This will help determine how exercise affects the rheological properties of red blood cells in this population.",[28],[33,283,284,285],"Exercise training","Erythrocyte","Rheology","2024-08-26",{"date":288,"type":41},"2024-08-28",{"date":290,"type":41},"2022-08-01",{"date":292,"type":21},"2025-07-31",{"name":294,"class":48},"Chang Gung Memorial Hospital",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":49},"100556095","response-of-arteriovenous-fistula-puncture-related-pain-to-cryotherapy-application-in-haemodialysis-patients-100556095","NCT06520631","Response Of Arteriovenous Fistula Puncture-related Pain To Cryotherapy Application In Haemodialysis Patients","Inclusion Criteria:\n\n* The study includes patients with ages from 30 to 50 years.\n* Patients able to report pain adequately.\n* Patients with end-stage kidney failure undergoing regular hemodialysis who have been treated for more than 3 months, at least twice per week, with arteriovenous fistula in use for more than 1 month are included in the study.\n\nExclusion Criteria:\n\nPatients with conditions such as\n\n* advanced age,\n* advanced diabetes,\n* cardiovascular insufficiency,\n* cold allergy,\n* Reynaud's phenomenon,\n* nerve and tissue damage,\n* fractures,\n* heart failure,\n* uncooperative patients,\n* cognitive impairment preventing a proper assessment of pain.","30 Years","50 Years",{"count":304,"type":21},90,[24],"Kidney disease occurs when kidney reduces its normal function, less than 30% of normal activity is related to a long-term condition. Therefore, people need to participate in a haemodialysis (HD) programme. In HD, blood is filtered by an external machine, done about three times a week and the access is gained through intermittent vascular cannulation.\n\nThe patients experience considerable pain due to the frequent insertion of AVF catheters.\n\nHemodialysis patients experience anxiety before needle insertion due to repeated punctures, and over 90% of patients experience acute pain during the process.\n\nPuncture-related pain during arteriovenous fistula (AVF) cannulation in particular is a crucial influential factor in quality of life.\n\nCryotherapy is one of the interventions used in several studies to alleviate the arteriovenous fistula puncture-related pain. It can be conduct by using ice packs and the results of the previous studies have also shown its positive effects on the relief of the fistula puncture-related pain in these patients.",[28],"2024-08-04",{"date":310,"type":41},"2024-08-06",{"date":312,"type":41},"2024-05-04",{"date":314,"type":21},"2024-08-31",{"name":196,"class":48},{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":117},"100537151","the-effect-of-the-care-given-to-hemodialysis-patients-on-comfort-level-and-complaints-100537151","NCT06274099","The Effect of the Care Given to Hemodialysis Patients on Comfort Level and Complaints","The Effect of Nursing Care Given According to Kolcaba's Comfort Theory on the Complaints and Comfort Level of Hemodialysis Patients","Inclusion criteria:\n\nClinical diagnosis of chronic renal failure Receiving 3 sessions of hemodialysis treatment per week Over 18 years old Must be able to communicate\n\nExclusion Criteria:\n\nHaving a psychiatric illness",{"count":324,"type":21},70,[24],"Kolcaba's comfort theory is a theory used by nurses to increase the comfort of patients. There are limited studies determining that nursing care provided according to this theory contributes to the increase in patients' comfort levels in various patient groups. This study will be carried out in the hemodialysis center of a public hospital located in the city center of Bingöl. Patients in the intervention group receiving hemodialysis treatment will be given nursing care by the researcher for 12 sessions during the sessions in which the patient receives hemodialysis treatment. In order to provide nursing care, nursing diagnoses suitable for the patient group will be determined in advance and the care the patient needs will be given according to these diagnoses.. If necessary, the researcher will add additional diagnoses to the preliminary diagnosis form and provide care.\n\nIn this research, the individual nursing care needs of the researcher patient will be determined. Individualized caregiving is unique to this study. Individually provided care is expected to increase patient comfort and satisfaction. Increased comfort will help the patient cope more easily with the disease and hemodialysis treatment symptoms. In addition, the results of individual care provided can guide nurses in their care behaviors. By adding this research to the literature, the groundwork will be laid for studies that will provide individual care to patients. It is expected that the results of this research will guide the planning of the research and the provision of individualized care in all patient groups, especially patients receiving hemodialysis treatment.",[28,328],"Nurse's Role",[133,330,331],"nursing care","comfort","2024-07-17",{"date":334,"type":41},"2024-07-18",{"date":336,"type":21},"2024-08",{"date":338,"type":21},"2024-12",{"name":340,"class":48},"Reva Balci Akpinar",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":49},"100366036","virtual-reality-intradialysis-last-vs-first-part-of-the-session-100366036","NCT04046042","Virtual Reality Intradialysis: Last vs. First Part of the Session","Virtual Reality Exercise Intradialysis: Tolerance and Dialysis Dose Effects During the Last vs. First Part of the Hemodialysis Session","VRI","Inclusion Criteria:\n\n* At least 3 months in hemodialysis treatment\n* Clinically stable\n\nExclusion Criteria:\n\n* Recent cardiac events (less than 3 months)\n* Unable to exercise",{"count":350,"type":21},50,[24],"The main objective of this investigation is to assess if an intradialysis virtual reality exercise program during the last two hours of the hemodialysis session results in greater hemodynamic stability than exercise performed during the first two hours of the hemodialysis session.\n\nThe secondary aims are to assess the impact of intradialysis virtual reality exercise during the last two hours of the hemodialysis session on dialysis efficacy, postdialysis molecules rebound, adherence to exercise, functional capacity, physical activity level, health-related quality of life, cognitive function, morbidity, frailty and dependency. We will also analyze the reliability of muscle strength assessment of lower limb muscles with a handheld dynamometer during hemodialysis.",[354,28],"End Stage Renal Disease on Dialysis",[356,357,358,359,360],"Exercise","Virtual reality","physical function","health-related quality of life","hemodynamic instability","2024-06-13",{"date":363,"type":41},"2024-06-14",{"date":365,"type":41},"2019-09-02",{"date":367,"type":21},"2024-08-30",{"name":369,"class":48},"Cardenal Herrera University",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":49},"100484348","study-of-markers-of-iron-metabolism-and-their-relationship-with-phosphocalcic-and-hepatic-metabolism-and-inflammation-in-hemodialysis-patients-100484348","NCT05586867","Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients","MARMEFE","Inclusion Criteria:\n\n* Adult dialysis patient\n* Patient able to understand the information necessary for the study and having signed his written consent to participate\n* Affiliated patient or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\n* Medically unstable or frail patient\n* Patient with hemoglobin less than 7g\u002Fdl\n* Patient with HIV+ or AIDS, patient with replicating hepatitis B or C\n* Patient participating in another clinical study requiring an additional blood sample\n* Patient benefiting from legal protection measures (guardianship, guardianship, etc.) adult under guardianship, guardianship or other legal protection, deprived of freedom by judicial or administrative decision\n* Pregnant, breastfeeding or parturient woman",{"count":378,"type":21},200,"From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure.\n\nThe study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients.\n\nThe main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.",[381,382,383,28],"Iron Metabolism Disorders","Calcium Phosphate Metabolism","Hepatic Metabolic Disorders","2022-10-17",{"date":386,"type":41},"2022-10-19",{"date":388,"type":41},"2021-12-01",{"date":390,"type":21},"2031-12-01",{"name":392,"class":48},"Ramsay Générale de Santé",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":399,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":408,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":117},"100470541","therapeutic-plantar-electrical-stimulation-intervention-during-hemodialysis-to-improve-balance-and-mobility-100470541","NCT05407207","Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility","Inclusion Criteria:\n\n* Male and female patients with diabetes receiving dialysis who are \\>40 years old.\n* Ambulatory (able to independently walk 20m with or without walking assistance).\n* Willing and able to provide informed consent.\n* Diabetes will be defined based on the American Diabetes Association (ADA) criteria (83).\n* Evidence of peripheral neuropathy and its severity will be determined based on a neurologic examination using criteria explained in the ADA statement.\n\nExclusion Criteria:\n\n* Have an active foot ulcer, an active infection, Charcot neuroarthropathy, or major foot amputation.\n* Patients with any clinically significant medical or psychiatric condition, or laboratory abnormality that would, in the judgment of the investigators, interfere with the ability to participate in the study.\n* Patients concurrently participating in exercise training; major hearing\u002Fvisual impairment; any patient with changes in psychotropic or sleep medications in the last 6 weeks.\n* If they were unlikely to fully comply with the follow-up protocol (e.g., travel plans).","40 Years",{"count":401,"type":21},100,[24],"A high prevalence of diabetes has been reported in Qatar with nearly 23% population suffering from the pandemic, thereby increasing the associated healthcare cost. Low compliance with exercise and physical activity in patients with diabetes increases foot risk complications, deteriorates health, and further increases economic costs. This is particularly true among patients with diabetes who are undergoing hemodialysis (HD) process. Exercise interventions have been shown to improve mobility and balance, reduce the incidence of falls, and improve peripheral blood flow, which is essential to reduce foot problems and peripheral arterial disease. However, uptake of exercise programs for individuals who are undergoing HD treatment has been limited. The three main factors limiting uptake and adherence among HD patients are time availability, post-dialysis fatigue, and transportation to exercise programs, which are usually offered in rehabilitation departments or cardiovascular centers but not in nephrology departments or in free-standing dialysis clinics. Many of these patients visit clinics 3 times a week to receive hemodialysis, providing an optimal opportunity for intervention. Thus the investigators are proposing an innovative intervention based on plantar electrical stimulation treatment during HD (3 times per week) to enhance balance and quality of life while reducing the risk of peripheral arterial diseases and diabetic foot ulcers, which are highly prevalent among people with diabetes and chronic kidney disease. This interdisciplinary study is based on preliminary studies, in which the investigators demonstrated that regular plantar electrical stimulation is an effective and practical therapy to enhance motor performance and plantar sensation in patients with diabetes. The scientific premise of the proposed intervention has been also supported by literature as well as three systematic reviews suggesting the effectiveness of electrical stimulation to reduce pain, improve balance, improve skin perfusion, and improve plantar sensation. In the context of this study, the investigators propose to bring an innovative technology based on an FDA-cleared bio-electric stimulation technology (BEST®) microcurrent platform, named Tennant Biomodulator® (Avazzia Inc., Dallas, TX, USA), which is a transcutaneous electrical nerve stimulator (TENS) and has been designed for symptomatic relief and management of chronic pain. However, the system was modified to provide electrical stimulation to the plantar area via two electrodes placed on the hind and forefoot area instead of the leg. The device has a 60-minute run cycle after which it automatically turns off. In the context of a previous study funded by QNRF, the investigators developed and tested 50 electrical stimulation units (which will be used in the context of the study), including 25 active systems and 25 placebo systems. The placebo systems are similar to active systems in the appearance and functioning of lights and indicators. However, they were programmed not to provide any electrical current.\n\nIn a preliminary study, the proof of concept of this revised technology was tested in the context of enhancing balance and skin perfusion in ambulatory patients with diabetes and peripheral neuropathy. In the context of this study, the investigators plan to translate this technology for routine treatment during HD sessions for patients with diabetes who are undergoing regular HD treatment. Using a double-blinded randomized-controlled model, the investigators will validate the effectiveness of this technology to enhance balance, reduce pain, and improve skin perfusion. One hundred (n=100) HD volunteers with diabetes will be recruited and randomized to either intervention (n=50) or control (CG: n=50) group for the purpose of this study. Plantar electrical stimulation will be provided during HD sessions, 3 times per week and for 12 weeks. Outcomes will be assessed at baseline, 6 weeks, and 12 weeks to examine the effectiveness of the proposed intervention to enhance balance, improve quality of life, and improve lower extremity skin perfusion among HD patients with diabetes.\n\nThis proposal is in line with Qatar National Priorities Research goals and if successful the result will open new doors to managing diabetes and kidney failure. In a setting where no therapeutic agents or interventions effectively address poor balance and loss of protective sensation among HD patients with diabetes and where affected individuals life with a heightened risk of developing a debilitating foot ulcer and quite possibly a disabling amputation, the potential impact from the plantar electrical stimulation system may offer the potential for significant clinical benefit, with very low risk, and with ease of implementation in routine care application for patients who are undergoing HD treatment.",[405,28,406,407],"Diabetes Mellitus","Cardiovascular Complication","Quality of Life",[409,410,411,412],"Preventive supplements","Treatment of diabetes related complications","Health intervention","Lifestyle intervention","2022-06-02",{"date":415,"type":41},"2022-06-07",{"date":417,"type":41},"2018-06-01",{"date":419,"type":21},"2022-11-11",{"name":421,"class":422},"Hamad Medical Corporation","INDUSTRY"]